Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 18Carcinoma, Non-Small-Cell Lung 6Glioma 5Brain Neoplasms 5Head and Neck Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Melanoma 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Breast Neoplasms 3Astrocytoma 3Stomach Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Pain 2Lung Neoplasms 2Gliosarcoma 2Central Nervous System Neoplasms 2Bone Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Stomatitis 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1

Interventions

Capecitabine 2veliparib 1peposertib 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Locally Advanced Rectal Cancer × Radiation × Clear all
NCT01589419 2017-11-20

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

AbbVie

Phase 1 Completed
32 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡